Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 117
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Infect Chemother ; 29(3): 281-283, 2023 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-36470374

RESUMEN

BACKGROUND: The transmission rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear when caregivers accompany pediatric COVID-19 patients in the same isolation room in a hospital setting. AIM: We investigated SARS-CoV-2 transmission from infected children to caregivers at our hospital. METHODS: This retrospective cohort study included 34 discordant pairs of patients admitted between September 2020 and April 2022. FINDINGS: The median ages of the children and caregivers were 3.7 years (interquartile range [IQR]: 1.6-8.1) and 33.1 years (IQR: 28.3-43.4), respectively. Of the 34 caregivers, 31 were mothers, two were fathers, and one was a relative. Sixteen caregivers received at least two doses of the mRNA vaccine. The mean duration of the hospital stays was 7.7 ± 4.1 days (range: 3-19). Two unvaccinated caregivers developed COVID-19 after admission; the onset was within 48 h after admission. It is likely that they had been infected in their household prior to admission, since the incubation period for COVID-19 is usually >2 days. CONCLUSIONS: Nosocomial SARS-CoV-2 transmission from infected children to caregivers was not confirmed in this study. The combination of negative-pressure rooms, vaccinations, and infection-control bundles appears to be effective at preventing SARS-CoV-2 transmission. It is acceptable to allow caregivers to accompany pediatric COVID-19 patients in a hospital ward if they can comply with basic infection control measures.


Asunto(s)
COVID-19 , Infección Hospitalaria , Humanos , Niño , Lactante , Preescolar , SARS-CoV-2 , COVID-19/epidemiología , Cuidadores , Estudios Retrospectivos , Pueblos del Este de Asia , Hospitales
2.
Circ J ; 85(8): 1329-1337, 2021 07 21.
Artículo en Inglés | MEDLINE | ID: mdl-33867407

RESUMEN

BACKGROUND: An association between atrial high-rate episode (AHRE) and stroke has been reported, although data for the Asian population are limited. This study aimed to investigate the role of AHRE in ischemic and major bleeding events in patients who underwent a cardiac implantable electronic device (CIED) procedure.Methods and Results:This single-center historical cohort study included 710 patients (age: 78±11 years, 374 women) who underwent a CIED-related procedure between October 2009 and September 2019 at Shimane Prefectural Central Hospital (median follow-up period: 4.5 [2.5, 7] years, 3439 person-years). Based on the maximum AHRE burden, patients were divided into: (1) <6 min; (2) ≥6 min to 24-h; and (3) ≥24-h groups. The cumulative incidence of ischemic (ischemic stroke, systemic embolism, and transient ischemic attack) and major bleeding (≥3 Bleeding Academic Research Consortium bleeding criteria) events after the procedure were compared. Uni- and multivariate analyses were performed to identify factors associated with these events. The incidence of both events increased with the rising AHRE burden, being significantly higher in the ≥24-h group than in the <6 min group. Multivariate analysis found age ≥85 years to be the only independent factor associated with both events. CONCLUSIONS: Longer AHRE duration is associated with a high number of major bleeding and ischemic events. Monitoring these bleeding risks is mandatory when clinicians are considering anticoagulation therapy for such patients.


Asunto(s)
Fibrilación Atrial , Anciano , Anciano de 80 o más Años , Anticoagulantes , Fibrilación Atrial/epidemiología , Estudios de Cohortes , Electrónica , Femenino , Hemorragia/epidemiología , Hemorragia/etiología , Humanos , Masculino , Factores de Riesgo , Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/etiología
3.
Microbiol Immunol ; 64(9): 630-634, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32484984

RESUMEN

Group B streptococcus (GBS) is a leading cause of neonatal infections. Most isolates are ß-hemolytic, and their activity is considered to be pivotal for GBS pathogenicity. We report a case of a neonate with meningitis caused by nonhemolytic GBS. The patient developed meningitis 3 days after birth. Genotyping was performed and the characteristics of the strain (GCMC97051) identified by whole genome sequence using next generation sequencing. GCMC97051 possesses genetic alterations such as disruption of cylA by IS1381A insertion and a frameshift mutation in cylE, resulting in a lack of hemolysis. Thus, nonhemolytic GBS can retain the potential to cause invasive infections.


Asunto(s)
Genoma Bacteriano , Meningitis Bacterianas/diagnóstico , Infecciones Estreptocócicas/diagnóstico , Streptococcus agalactiae/genética , Preescolar , Proteínas Hemolisinas/genética , Humanos , Masculino , Meningitis Bacterianas/microbiología , Filogenia , Infecciones Estreptocócicas/microbiología , Streptococcus agalactiae/clasificación , Streptococcus agalactiae/aislamiento & purificación , Factores de Virulencia/genética , Secuenciación Completa del Genoma
4.
Pacing Clin Electrophysiol ; 43(8): 838-846, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32588437

RESUMEN

BACKGROUND: Telethonin (TCAP) is a Z-disk protein that maintains cytoskeletal integrity and various signaling pathways in cardiomyocytes. TCAP is shown to modulate α-subunit of the human cardiac sodium channel (hNav 1.5) by direct interactions. Several TCAP variants are found in cardiomyopathies. We sought to investigate whether TCAP variants are associated with arrhythmia syndromes. METHODS: Mutational analyses for TCAP were performed in 303 Japanese patients with Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy, and J-wave pattern ECG. Using patch-clamp techniques, electrophysiological characteristics of hNav 1.5 were studied in HEK-293 cells stably expressing hNav 1.5 and transiently transfected with wild-type (WT) or variant TCAP. RESULTS: We identified two TCAP variants, c.145G>A:p.E49K and c.458G>A:p.R153H, in four individuals. p.E49K was found in two patients with ARVC or BrS. p.R153H was found in two patients with BrS or J-wave pattern ECG. No patient had variant hNav 1.5. Patch-clamp experiments demonstrated that peak sodium currents were significantly reduced in cells expressing p.R153H and p.E49K compared with WT-TCAP (66%, p.R153H; 72%, p.E49K). Voltage dependency of peak IV curve was rightward-shifted by 5 mV in cells expressing p.E49K compared with WT-TCAP. Voltage dependency of activation was not leftward-shifted by p.R153H, while voltage dependency of steady-state inactivation was leftward-shifted by p.E49K. CONCLUSIONS: We found two TCAP variants in the patients with BrS, J-wave pattern ECG, and ARVC that can cause loss-of-function of the hNav 1.5 in heterologous expression systems. Our observation suggests that these variants might impair INa and be associated with the patients' electrophysiological phenotypes. Further studies linking our experimental data to clinical phenotypes are warranted.


Asunto(s)
Displasia Ventricular Derecha Arritmogénica/genética , Síndrome de Brugada/genética , Conectina/genética , Canal de Sodio Activado por Voltaje NAV1.5/genética , Adolescente , Adulto , Anciano , Displasia Ventricular Derecha Arritmogénica/fisiopatología , Síndrome de Brugada/fisiopatología , Electrocardiografía , Células HEK293 , Humanos , Masculino , Persona de Mediana Edad , Técnicas de Placa-Clamp
5.
J Infect Chemother ; 25(2): 141-146, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30100399

RESUMEN

Lactococcus lactis is a rare causative organism in humans. Cases of L. lactis infection have only rarely been reported. However, because it is often difficult to identify by conventional commercially available methods, its incidence may be underestimated. We herein report the case of a 70-year-old man with cholangiocarcinoma who developed L. lactis cholangitis and review previously reported cases of L. lactis infection. Our case was confirmed by matrix-assisted desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). This case shows L. lactis is a potential causative pathogen of cholangitis and that MALDI-TOF MS can be useful for the rapid and accurate identification of L. lactis infection. We searched the literature for published case reports on cholangitis and any other infections caused by L. lactis, and thereby identified 36 cases, including our case. At least 66.7% (n = 24) of the cases had significant underlying conditions; 15 of the cases involved patients with an immunocompromised status. At least 41.7% (n = 15) had a significant food consumption history, such as the consumption of unpasteurized dairy products. The clinical sources of L. lactis were diverse and endocarditis was the most common diagnosis (n = 8), followed by hepatobiliary infection (n = 6), central nervous system infection (n = 5), and peritonitis (n = 4). The prognosis was favorable in most cases.


Asunto(s)
Bacteriemia/diagnóstico , Colangitis/diagnóstico , Infecciones por Bacterias Grampositivas/diagnóstico , Lactococcus lactis , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción/métodos , Anciano , Humanos , Masculino , Tipificación Molecular
6.
Circulation ; 135(23): 2255-2270, 2017 Jun 06.
Artículo en Inglés | MEDLINE | ID: mdl-28341781

RESUMEN

BACKGROUND: The genotype-phenotype correlation of SCN5A mutations as a predictor of cardiac events in Brugada syndrome remains controversial. We aimed to establish a registry limited to probands, with a long follow-up period, so that the genotype-phenotype correlation of SCN5A mutations in Brugada syndrome can be examined without patient selection bias. METHODS: This multicenter registry enrolled 415 probands (n=403; men, 97%; age, 46±14 years) diagnosed with Brugada syndrome whose SCN5A gene was analyzed for mutations. RESULTS: During a mean follow-up period of 72 months, the overall cardiac event rate was 2.5%/y. In comparison with probands without mutations (SCN5A (-), n=355), probands with SCN5A mutations (SCN5A (+), n=60) experienced their first cardiac event at a younger age (34 versus 42 years, P=0.013), had a higher positive rate of late potentials (89% versus 73%, P=0.016), exhibited longer P-wave, PQ, and QRS durations, and had a higher rate of cardiac events (P=0.017 by log-rank). Multivariate analysis indicated that only SCN5A mutation and history of aborted cardiac arrest were significant predictors of cardiac events (SCN5A (+) versus SCN5A (-): hazard ratio, 2.0 and P=0.045; history of aborted cardiac arrest versus no such history: hazard ratio, 6.5 and P<0.001). CONCLUSIONS: Brugada syndrome patients with SCN5A mutations exhibit more conduction abnormalities on ECG and have higher risk for cardiac events.


Asunto(s)
Síndrome de Brugada/genética , Electrocardiografía , Genotipo , Mutación/genética , Canal de Sodio Activado por Voltaje NAV1.5/genética , Fenotipo , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Síndrome de Brugada/epidemiología , Síndrome de Brugada/fisiopatología , Niño , Preescolar , Electrocardiografía/métodos , Femenino , Estudios de Seguimiento , Humanos , Japón/epidemiología , Masculino , Persona de Mediana Edad , Sistema de Registros , Adulto Joven
7.
Circ J ; 83(1): 52-55, 2018 12 25.
Artículo en Inglés | MEDLINE | ID: mdl-30344201

RESUMEN

BACKGROUND: Implantable cardioverter defibrillators (ICDs) are being used with increasing frequency in children. Our aim was to examine the current trend of pediatric ICD implantation in Japan. Methods and Results: Data was extracted from the Japanese Cardiac Device Treatment Registry (JCDTR), a nation-wide registry started in 2006. All patients aged less than 18 years who had an ICD implantation registered between 2006 and 2016 were included in the analysis. A total of 201 patients were included, with a median age of 16 years (range 1-18). The underlying cardiac diagnosis was primary electrical disease (67%), cardiomyopathy (26%) and congenital heart disease (4%), with idiopathic ventricular fibrillation (29%) and long QT syndrome (21%) being the 2 most common diagnoses. Implantation indication was primary prevention in only 30 patients (15%). There were 27 patients (13%) aged ≤12 years, with a larger proportion of patients with cardiomyopathy (33%). The indication in younger children was secondary prevention in all cases. Younger children may be under-represented in our study given the nature of the database as it is a predominantly adult cardiology database. CONCLUSIONS: In the past decade, ICD implantation has been performed in approximately 20 children per year in Japan, mostly for secondary prevention. There was no increase in the trend nor a change in age distribution.


Asunto(s)
Arritmias Cardíacas/terapia , Bases de Datos Factuales , Desfibriladores Implantables/tendencias , Sistema de Registros , Adolescente , Arritmias Cardíacas/epidemiología , Arritmias Cardíacas/fisiopatología , Niño , Preescolar , Femenino , Humanos , Masculino
8.
Circ J ; 81(12): 1798-1806, 2017 Nov 24.
Artículo en Inglés | MEDLINE | ID: mdl-28626201

RESUMEN

BACKGROUND: Randomized control trials comparing the effectiveness of cardiac resynchronization therapy devices, with (CRT-D) or without (CRT-P) a defibrillator, are scarce in heart failure patients with no prior sustained ventricular tachyarrhythmias.Methods and Results:The Japan Cardiac Device Treatment Registry (JCDTR) has data for 2714 CRT-D and 555 CRT-P recipients for primary prevention with an implantation date between January 2011 and August 2015. Of these patients, follow-up data were available for 717. Over the mean follow-up period of 21 months, Kaplan-Meier curves of survival free of combined events for all-cause death or heart failure hospitalization (whichever came first) diverged between the CRT-D (n=620) and CRT-P (n=97) groups with a rate of 22% vs. 42%, respectively, at 24 months (P=0.0011). However, this apparent benefit of CRT-D over CRT-P was no longer significant after adjustment for covariates. With regard to mortality, including heart failure death or sudden cardiac death, there was no significant difference between the 2 groups. CONCLUSIONS: In patients without sustained ventricular tachyarrhythmias enrolled in the JCDTR, there was no significant difference in mortality between the CRT-D and CRT-P groups, despite a lower trend in CRT-D recipients. This study was limited by large clinical and demographic differences between the 2 groups.


Asunto(s)
Terapia de Resincronización Cardíaca/métodos , Desfibriladores Implantables , Insuficiencia Cardíaca/terapia , Hospitalización , Anciano , Anciano de 80 o más Años , Femenino , Insuficiencia Cardíaca/mortalidad , Humanos , Japón , Masculino , Persona de Mediana Edad , Prevención Primaria , Sistema de Registros , Análisis de Supervivencia
11.
Circ J ; 80(7): 1548-55, 2016 Jun 24.
Artículo en Inglés | MEDLINE | ID: mdl-27251064

RESUMEN

BACKGROUND: The proportion of patients with atrial fibrillation (AF) treated with anticoagulation varies from country to country. In Japan, little is known about regional differences in frequency of warfarin use or prognosis among patients with non-valvular AF (NVAF). METHODS AND RESULTS: In J-RHYTHM Registry, the number of patients recruited from each of 10 geographic regions of Japan was based on region population density. A total of 7,406 NVAF patients were followed up prospectively for 2 years. At baseline, significant differences in various clinical characteristics including age, sex, type of AF, comorbidity, and CHADS2score, were detected among the regions. The highest mean CHADS2score was recorded in Shikoku. Frequency of warfarin use differed between the regions (P<0.001), with lower frequencies observed in Hokkaido and Shikoku. Baseline prothrombin time international normalized ratio differed slightly but significantly between the regions (P<0.05). On univariate analysis, frequency of thromboembolic events differed among the regions (P<0.001), with the highest rate seen in Shikoku. An inverse correlation was detected between frequency of thromboembolic and of major hemorrhagic events (P=0.062). On multivariate analysis, region emerged as an independent risk for thromboembolism. CONCLUSIONS: Thromboembolic risk, frequency of warfarin use, and intensity and quality of warfarin treatment differed significantly between geographic regions of Japan. Region was found to be an independent predictor of thromboembolic events. (Circ J 2016; 80: 1548-1555).


Asunto(s)
Fibrilación Atrial/tratamiento farmacológico , Sistema de Registros , Tromboembolia/tratamiento farmacológico , Warfarina/administración & dosificación , Anciano , Anciano de 80 o más Años , Fibrilación Atrial/complicaciones , Humanos , Persona de Mediana Edad , Factores de Riesgo , Tromboembolia/etiología
16.
J Cardiovasc Electrophysiol ; 25(5): 522-530, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24400717

RESUMEN

BACKGROUND: Brugada syndrome (BrS) is an inherited disease characterized by right precordial ST segment elevation on electrocardiograms (ECGs) that predisposes patients to sudden cardiac death as a result of polymorphic ventricular tachyarrhythmia or ventricular fibrillation (VF). In BrS patients, except for SCN5A, mutations in other responsible genes are poorly elucidated. METHODS AND RESULTS: We identified 4 KCNH2 mutations, T152I, R164C, W927G, and R1135H, in 236 consecutive probands with BrS or Brugada-like ECG. Three of these mutation carriers showed QTc intervals shorter than 360 milliseconds and 1 experienced VF. We performed patch-clamp analyses on I(Kr) reconstituted with the KCNH2 mutations in Chinese hamster ovary cells and compared the phenotypes of the patients with different genotypes. Three mutations, R164C, W927G, and R1135H, increased I(Kr) densities. Three mutations, T152I, R164C, and W927G, caused a negative shift in voltage-dependent activation curves. Only the R1135H mutant channel prolonged the deactivation time constants. We also identified 20 SCN5A and 5 CACNA1C mutation carriers in our cohort. Comparison of probands' phenotypes with 3 different genotypes revealed that KCNH2 mutation carriers showed shorter QTc intervals and SCN5A mutation carriers had longer QRS durations. CONCLUSIONS: All KCNH2 mutations that we identified in probands with BrS exerted gain-of-function effects on I(Kr) channels, which may partially explain the ECG findings in our patients.


Asunto(s)
Síndrome de Brugada/genética , Canales de Potasio Éter-A-Go-Go/genética , Mutación , Potenciales de Acción , Adulto , Animales , Síndrome de Brugada/diagnóstico , Síndrome de Brugada/metabolismo , Síndrome de Brugada/fisiopatología , Síndrome de Brugada/terapia , Células CHO , Canales de Calcio Tipo L/genética , Cricetulus , Análisis Mutacional de ADN , Canal de Potasio ERG1 , Electrocardiografía , Canales de Potasio Éter-A-Go-Go/metabolismo , Predisposición Genética a la Enfermedad , Pruebas Genéticas/métodos , Humanos , Cinética , Masculino , Persona de Mediana Edad , Canal de Sodio Activado por Voltaje NAV1.5/genética , Técnicas de Placa-Clamp , Fenotipo , Pronóstico , Transfección
17.
Circ J ; 78(8): 1989-91, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25030300

RESUMEN

BACKGROUND: Little is known regarding the appropriate duration for driving restrictions after inappropriate implantable cardiac shock device (ICSD) therapy. METHODS AND RESULTS: We evaluated the Nippon Storm Study data, and found that inappropriate ICSD therapy occurred in 114 (7.6%) patients during a median follow-up of 464 days. Among those patients, 25 experienced further inappropriate ICSD therapy during a subsequent median follow-up of 380 days. Time-dependent recurrence of inappropriate ICSD therapy occurred in 19 (76%) patients within 180 days. CONCLUSIONS: The interval for driving restrictions after inappropriate ICSD therapy can be reduced.


Asunto(s)
Conducción de Automóvil , Tormentas Ciclónicas , Desfibriladores Implantables , Choque Cardiogénico/prevención & control , Anciano , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad
19.
J Arrhythm ; 40(1): 30-37, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38333398

RESUMEN

Background: Temporal change in outcomes of heart failure patients receiving cardiac resynchronization therapy with a defibrillator (CRT-D) is unknown. Methods: We assess outcomes and underlying heart diseases of patients receiving CRT-D with analyzing database of the Japan cardiac device treatment registry (JCDTR) at the implantation year 2011-2015 and New JCDTR at the implantation year 2018-2021. Results: Proportion of nonischemic heart diseases was about 70% in both the groups (JCDTR: 69%; New JCDTR: 72%). Cardiac sarcoidosis increased with the rate of 5% in the JCDTR to 9% in the New JCDTR group. During an average follow-up of 21 months, death from any cause occurred in 167 of 906 patients in the JCDTR group (18%) and 79 of 611 patients in the New JCDTR group (13%) (adjusted hazard ratio [aHR] in the New JCDTR group, 0.72; 95% confidence interval [CI]: 0.55-0.94; p = .017). The superiority was mainly driven by reduction in the risk of noncardiac death. With regard to appropriate and inappropriate implantable cardioverter-defibrillator (ICD) therapy, there was a significant reduction in the New JCDTR group versus the JCDTR group (aHR in the New JCDTR group, 0.76; 95% CI: 0.59-0.98; p = .032 for appropriate ICD therapy; aHR in the New JCDTR group, 0.24; 95% CI: 0.12-0.50; p < .0001 for inappropriate ICD therapy). Conclusions: All-cause mortality was reduced in CRT-D patients implanted during 2018-2021 compared to those during 2011-2015, with a significant reduction in noncardiac death.

20.
Circ Rep ; 6(10): 415-423, 2024 Oct 10.
Artículo en Inglés | MEDLINE | ID: mdl-39391549

RESUMEN

Background: The relationship between changes in the left atrial volume index (LAVI) post-catheter ablation (CA) and long-term prognostic events in patients with persistent atrial fibrillation (AF) remains unclear. We evaluated the incidence of major adverse clinical events (MACE), including all-cause death, unplanned heart failure hospitalization, and unplanned cardiovascular hospitalization using pre- and post-CA LAVI. Methods and Results: We collected data retrospectively from 150 patients with persistent AF who underwent their first CA. LAVI was calculated during preprocedural echocardiography under AF rhythm (pre-CA LAVI) and 3 months post-CA under sinus rhythm (post-CA LAVI). The cumulative incidence of MACE was compared among 3 subgroups based on the cutoff values of pre-CA (45.5 mL/m2) and post-CA (46.5 mL/m2; both determined using the c-statistic) LAVI. The subgroup of a pre-CA LAVI >45.5 mL/m2 with a post-CA LAVI >46.5 mL/m2 (n=45) had a significantly higher MACE incidence compared with other subgroups (P=0.002). Multivariate analysis identified this subgroup as independently at higher risk for MACE. The subgroup of a pre-CA LAVI >45.5 mL/m2 with a post-CA LAVI ≤46.5 mL/m2 (n=49) had an incidence comparable with those with pre-CA LAVI ≤45.5 mL/m2 (n=56) and exhibited a significantly greater reduction in LAVI than other subgroups did (P<0.001). Conclusions: Combining pre-CA and post-CA LAVIs is valuable in stratifying long-term MACE development risk following CA.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA